The analogue, liraglutide, was effective in clinical studies (the LEAD trials [16]) and was subsequently tested in a cardiovascular outcome trial, the LEADER trial [17], as demanded by the FDA for new antidiabetic agents
Global GLP-1 receptor agonist market is expected to witness lucrative growth over the forecast period as increasing number of patients are opting for GLP-1 drugs due to their greater efficacy and lesser side effects compared to conventional diabetes medications
Its really important to not use the scale as the only outcome of whether you should stay on this medication
"We believe it will expand access and options for patients," Dr
approved weekly GLP-1 therapies similarly specify no preferred injection time, emphasising consistency over hour of day
Gram-positive and gram-negative anaerobic and aerobic bacteria are both susceptible to the wide-ranging effects of the nonabsorbable oral antibiotic rifaximin (62)